Active Biotech Regains Rights to Laquinimod from Teva, Plans to Continue Work on Potential MS Oral Therapy
Active Biotech: Latest News | Tracxn
Active Biotech - News, Articles etc. - European Pharmaceutical Review
Tweets with replies by Teva Pharmaceuticals (@TevaUSA) / Twitter
Teva Relinquishes Laquinimod, Returning the Rights to Active Biotech - Pharmaceutical Processing World
The top 10 leading biotech companies | biotechworldwide.net
Teva and Active Biotech Announce CONCERTO trial of Laquinimod trial fails
Teva and Active Signs Agreement to Study Laquinimod as Treatment for Neurological Disease
Teva drops laquinimod for most common form of MS after failed trial - PMLiVE
Active Biotech and Teva remain committed to clinical development program for multiple sclerosis
Heart Incidents End Parts of Two Studies by Teva, Active Biotech - WSJ
Teva backs laquinimod for MS despite CHMP rejection - PMLiVE
Teva, Active Biotech enrol first patient in RRMS drug Phase III study - Clinical Trials Arena
3 Reasons to Buy Teva Right Now - TheStreet
Prostate Cancer Therapeutics Market Competitive Landscape
Laquinimod, an Oral Product in Development for the Treatment of Relapsing Remitting Multiple Sclerosis Steve Glenski, PharmD Medical Affairs Teva Neuroscience. - ppt download
Teva Pharmaceuticals - Wikipedia
Teva and Active Biotech Expand Investigational MS Treatment Program
Teva Pharmaceuticals (@TevaUSA) / Twitter
Teva: Leverage A Concern (NYSE:TEVA) | Seeking Alpha
CHMP says no to Laquinimod
After Failing Phase III, Active Biotech is back to square one - Labiotech.eu
Teva Pharmaceutical Industries Ltd - News, Articles etc. - European Pharmaceutical Review
Active Biotech provides update on laquinimod in Huntington's disease - Huntington's Disease News
Active Biotech Pivots Away from MS and Huntington's Disease, Goes in New Direction | BioSpace
